Ilumina ups guidance after Q2 results


Ilumina (ILMN +2.5%) Q2 results: Total Revenue: $447.6M (+29.3%), Product Revenue: $390.8M (+24.7%); Cost of Revenue: $147.0M (+19.8%); R&D Expense: $83.0M (+22.7%); SG&A Expense: $114.6M (+29.2%); Operating Income: $100.2M (+67.0%); Net Income: $46.6M (+29.8%); EPS: $0.31 (+19.2%); CF Ops: $178.0M (+100.9%); Quick Assets: $1,103.1M (-5.4%).

2014 Guidance: Revenue growth: 25 - 26%; non-GAAP EPS: $2.26 - 2.28.

From other sites
Comments (5)
  • LONGTERM RICHARD
    , contributor
    Comments (49) | Send Message
     
    Illumina's Q2 results are a continuation of their long term trend:
    Total Revenue + 29.3%
    Net Income + 29.8%
    2014 Revenue growth ( Guidance ) + 25-26 %
    ILMN has a great track record and a high place in my long term " growth category " holdings;
    I recentlly sold DRQ and added to my ILMN.--No Regrets
    23 Jul 2014, 08:08 PM Reply Like
  • BRZ
    , contributor
    Comments (5) | Send Message
     
    Why would $ILMN drop 3% after great earnings call?
    24 Jul 2014, 11:47 AM Reply Like
  • LONGTERM RICHARD
    , contributor
    Comments (49) | Send Message
     
    To: BRZ -- Good question and I don't have the answer yet. Hopefully it's something basic like
    speculators taking profits on the big run up yesterday. I'm unaware of any downside info and have no reason for concern at this time.
    24 Jul 2014, 03:35 PM Reply Like
  • LONGTERM RICHARD
    , contributor
    Comments (49) | Send Message
     
    To: BRZ-- I think your question is answered by Investors Business Daily, July 25, Page A4--
    in a 2 column article that said ' Biotech stocks in general fell t
    25 Jul 2014, 03:56 PM Reply Like
  • LONGTERM RICHARD
    , contributor
    Comments (49) | Send Message
     
    T0: BRZ-- I Think your question is answered by Investors Business Daily,July 25, Page A4-
    2 column article that said: " Biotech stocks in general fell, especially the big caps Gilead and Illumina--biotech stocks have been volatile in the wake of Janet Yellen's comments last week that biotech valuations were " stretched " based on price to earnings ratios." ---Sorry for the delay in writing this --I had keyboard problems.
    26 Jul 2014, 01:11 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs